External radiotherapy and anaemia treatment: State of the art

Swiss Medical Weekly

Volumn 135, Issue 1-2, 2005, Pages 4-10

  Ozsahin, Mahmut ^a   Azria, David ^b   Beer, Karl ^c   Mirimanoff, René Olivier ^a   Zoubair, Abderrabim ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b CENTRE VAL D AURELLE   (France)

^c UNIVERSITY OF BERN   (Switzerland)

Author keywords

Anaemia; Erythropoietin; Radiotherapy

Indexed keywords

EFAPROXIRAL; ERYTHROPOIETIN; ETANIDAZOLE; FERROUS SULFATE; FLUOROURACIL; MITOMYCIN C; PENTOXIFYLLINE; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BLEEDING; CANCER; CANCER RADIOTHERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; HUMAN; HYPERTENSION; HYPOXIA; LUNG EMBOLISM; MULTIMODALITY CANCER THERAPY; PURE RED CELL ANEMIA; QUALITY OF LIFE; RADIOSENSITIVITY; REVIEW;

EID: 12944298772     PISSN: 14247860     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (61)

1. Cella D. Factors influencing quality of life in cancer patients: Anemia and fatigue. Semin Oncol 1998;25:43-6.
2. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst 1999;91:511-4.
3. Platanias LC, Miller CB, Mick R, et al. Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients. J Clin Oncol 1991;9:2021-6.
4. Girinski T, Pejovic-Lenfant MH, Bourhis J, et al. Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: Results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 1989;16:3 7-42.
5. 2 predicts survival in advanced cancer of the uterine cervix. Radiother Oncol 1993;26:45-50.
6. Lartigau E, Vitu L, Haie-Meder C, et al. Feasibility of measuring oxygen tension in uterine cervix carcinoma. Eur J Cancer 1992;28A:1354-7.
7. Tarnawski R, Skladowski K, Majiejewski B. Prognostic value of hemoglobin concentration in radiotherapy for cancer of supraglottic larynx. Int J Radiat Oncol Biol Phys 1997;38:1007-11.
8. Van Acht MJ, Hermans J, Boks DE, et al. The prognostic value of hemoglobin and a decrease in hemoglobin during radiotherapy in laryngeal carcinoma. Radiother Oncol 1992;23:229-35.
9. Fein DA, Lee WR, Hanlon AL, et al. Pre-treatment hemoglobin level influences local control and survival of T1-T2 carcinomas of the glottic larynx. J Clin Oncol 1995;13:2077-83.
10. Dubray B, Mosseri V, Brunin F, et al. Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: A prospective study. Radiology 1996;201:553-8.
11. Guttenberger R, Lutterbach J, Roth A, et al. Hemoglobin levels predict locoregional control after post-operative radiotherapy for advanced head and neck cancer. Eur J Cancer 1997;33:102-3.
12. Brizel DM, Sibley GS, Prosnitz LR, et al. Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 1997;38:285-9.
13. Demetri GD, Kris M, Wade J, et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alpha is independent of disease response or tumor type: Results from a prospective community oncology study. J Clin Oncol 1998;16:3412-25.
14. Boogaerts M, Coiffier B, Kainz C, et al. Impact of epoetin-β on quality of life in patients with malignant disease. Br J Cancer 2003;88:988-95.
15. Case Jr DC, Bukowski RM, Carey RW, et al. Recombinant human erythropoietin therapy for anemic cancer patients on combination chemotherapy. J Natl Cancer Inst 1993;85:801-6.
16. Littlewood TJ, Bajetta E, Nortier JW, et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-74.
17. Thomas ML. Anemia and quality of life in cancer patients: impact of transfusion and erythropoietin. Med Oncol 1998;15 (Suppl. 1):S13-18.
18. Shasha D, George M. Once-weekly dosing of epoetin alfa increases hemoglobin levels and improves quality of life in anemic cancer patients receiving radiotherapy and chemotherapy. Blood 2000;96:434a (abstract 1866).
19. Hall EJ. Radiobiology for the Radiologist. 5th edition, J. B. Lippincott Company, Philadelphia, 2000.
20. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissue at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-42.
21. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995;333:1757-63.
22. Vaupel P, Schlenger K, Knoop C, et al. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res 1991;51:3316-22.
23. Groebe K. Impact of anaemia on the oxygenation status of tumours: A theoretical study. Stuttgart, Germany. Wissenschaftliche Verlagsgesellschaft; 1999.
24. Höckel M, Vaupel P. Tumor hypoxia: Definition and current clinical, biologic and molecular aspects. J Natl Cancer Inst 2001;93:266-76.
25. Brizel DM, Scully SP, Harrelson JM, et al. Tumour oxygenation predicts for likelihood of distant metastases in human soft tissue sarcoma. Cancer Res 1996;56:941-3.
26. Graeber TG, Osmanian C, Jacks T, et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996;379:88-91.
27. Vaupel P, Mayer A, Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004;381:335-54.
28. Ludwig LL, Fritz E. Anemia in cancer patients. Semin Oncol 1998;25:2-6.
29. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma: results of the Danish head and neck cancer study (DAHANCA) protocol 5-85. Radiother Oncol 1998,46:135-46.
30. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistance in tumors by the use of oxygen radiosensitizers. Semin Radiat Oncol 1996;6:10-21.
31. Lee WR, Berkey B, Marcial V, et al. Anemia is associated with decreased survival and increased loco-regional failure in patients with locally advanced head and neck carcinoma: A secondary analysis of RTOG 85-27. Int J Radiat Oncol Biol Phys 1998;42:1069-75.
32. Overgaard J, Hansen HS, Anderson AP, et al. Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: Report from of the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 1989;16:1065-8.
33. Kunugita N, Kohshi K, Kinoshita Y, et al. Radiotherapy after hyperbaric oxygenation improves radioresponse in experimental tumor models. Cancer Lett 2001;164:149-54.
34. Kaanders JH, Bussink J, van der Kogel AJ. Clinical studies of hypoxia modification in radiotherapy. Semin Radiat Oncol 2004;14:233-40.
35. Suh JH. Efaproxiral: a novel radiation sensitiser. Expert Opin Investig Drugs 2004;13:543-50.
36. Zywietz F, Bohm L, Sagowski C, et al. Pentoxifylline enhances tumor oxygenation and radiosensitivity in rat rhabdomyosarcomas during continuous hyperfractionated irradiation. Strahlenther Onkol 2004;180:306-14.
37. 7 Kelleher DK, Thews O, Vaupel P. Can erythropoietin improve tumor oxygenation? Strahlenther Onkol 1998;S4:20-3.
38. Dunphy FR, Harrison BR, Dunleavy TL, et al. Erythropoietin reduces anemia and transfusions. Cancer 1999;86:1362-7.
39. Lavey RS, Dempsey WH. Erythropoietin increases hemoglobin in cancer patients during radiation therapy. Int J Radiat Oncol Biol Phys 1993;27:1147-52.
40. Vijayakumar S, Roach M III, Wara W, et al. Effect of subcutaneous recombinant human erythropoietin in cancer patients receiving radiotherapy: preliminary results of a randomised, open-labelled, phase II trial. 1993;26:721-9.
41. Dusenbery KE, Mcguire WA, Holt PJ, et al. Erythropoietin increases hemoglobin during radiation therapy for cervical cancer. Int J Radiat Oncol Biol Phys 1994;29:1079-84.
42. Henke M, Guttenberger R, Barke A, et al. Erythropoeitin for patients undergoing radiotherapy: a pilot study. Radiother Oncol 1999;50:185-90.
43. Rizzo JD, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083.
44. Glaser C, Millesi W, Wanschitz F, et al. R-Hu erythropoietin treatment increases efficacy of neoadjuvant radiochemotherapy and improves cancer free survival of patients with oral squamous cell carcinoma: a 17 month follow-up. J Clin Oncol 1999;S18:399a.
45. Glaser CM, Millesi W, Kornek G, et al. Impact of hemoglobin level and use of recombinant erythropoietin on efficacy of preoperative chemoradiation therapy for squamous cell carcinoma of the oral cavity and oropharynx. Int J Radiat Oncol Biol Phys 2001;50:705-15.
46. Blohmer JU, et al. 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer. Proc. ASCO 2003; abstract 1798 (www.asco.org).
47. Henke M, Laszig R, Rübe C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-60.
48. Correspondance to the Lancet 2004;363:78 and 992-994.
49. Pickles T, Liu M, Berthelet E, et al. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol 2004;171:1543-6.
50. Videtic GM, Stitt LW, Dar AR, et al. Continued cigarette smoking by patients receiving concurrent chemoradiotherapy for limited-stage small-cell lung cancer is associated with decreased survival. J Clin Oncol 2003;21:1544-9.
51. Grau C, Nordsmark M, Khalil AA, et al. Effect of carbon monoxide breathing on hypoxia and radiation response in the SCCVII tumor in vivo. Int J Radiat Oncol Biol Phys 1994;29:449-54.
52. Vaupel P, Thews O, Mayer A, et al. Oxygenation status of gynecologic tumors: what is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-31.
53. Cremieux P, Finkelstein SN, Berndt ER, et al. Cost-effectiveness, quality-adjusted life year and supportive care: recombinant human erythropoietin as a treatment of cancer-associated anemia. Pharmacoeconomics 1999;16:459-72.
54. Casadevall N, et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med 2002;346:469-75.
55. Porter S. Human immune response to recombinant human proteins. J Pharma Sci 2001;90:1-11.
56. Casadevall N. Epoetin-induced autoimmune pure red cell aplasia. Hem J 2004;5:S104-S109.
57. Thews O, König R, Kelleher DK, et al. Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anemia. Br J Cancer 1998;78:752-66.
58. Stuben G, Wachek V, Kodym R, et al. Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anemic nude mice. J Cancer Res Clin Oncol 2001;127:346-50.
59. Stuben G, Pöttgen C, Knühmann K, et al. Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358-62.
60. Stuben G, Thews O, Pöttgen C, et al. Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003b;179:620-5.
61. Thews O, Kelleher D, Vaupel P. Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-61.